Vivos Inc. (RDGL)
OTCMKTS · Delayed Price · Currency is USD
0.0819
-0.0011 (-1.33%)
At close: Jul 10, 2026
Vivos Revenue
Vivos had revenue of $36.07K in the quarter ending March 31, 2026, with 34.84% growth. This brings the company's revenue in the last twelve months to $77.70K, up 54.65% year-over-year. In the year 2025, Vivos had annual revenue of $68.38K with 144.25% growth.
Revenue (ttm)
77.70K
Revenue Growth
+54.65%
P/S Ratio
520.59
Revenue / Employee
77.70K
Employees
1
Market Cap
40.45M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 68.38K | 40.38K | 144.25% |
| Dec 31, 2024 | 28.00K | 8.50K | 43.56% |
| Dec 31, 2023 | 19.50K | -17.00K | -46.57% |
| Dec 31, 2022 | 36.50K | 21.61K | 145.17% |
| Dec 31, 2021 | 14.89K | 7.89K | 112.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zomedica | 34.33M |
| Kelyniam Global | 2.67M |
| PetVivo Holdings | 1.14M |
| Family Office of America | 1.00M |
| Guided Therapeutics | 767.00K |
| Tian'an Technology Group | 734.89K |
| Positron | 453.12K |
| CS Diagnostics | 204.00K |
Vivos News
- 4 days ago - Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™ - GlobeNewsWire
- 4 weeks ago - Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing - GlobeNewsWire
- 5 weeks ago - Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™ - GlobeNewsWire
- 5 months ago - Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites - GlobeNewsWire
- 5 months ago - Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ - GlobeNewsWire
- 5 months ago - Vivos Inc Updates Human Therapy Progress in India - GlobeNewsWire
- 5 months ago - Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals - GlobeNewsWire
- 7 months ago - Vivos Inc Summarizes Progress in its Animal Therapy Division - GlobeNewsWire